Separate names with a comma.
Strong close in sweden
Huge upside potential here
Calliditas secures a US Fast Track Designation (FTD) for Setanaxib in PBC ahead of the pivotal study (Redeye) 2021-08-09 12:13 Calliditas is in a...
Calliditas and STADA partner to bring a specialty therapy focused on downregulating IgA1 to European patients. If approved, it would be the...
Still some time left, but easy minimum 20-40 % from here.
Nefecon is the first potential drug for IgAN, an orphan disease with a blockbuster potential of 4-5 billion USD. The European market is around...
I believe we'll see big movements before the inclusion in Russell 2000 index. People will front-run it no doubt. This in combination with the...
I hope DMC stops the study, it's not ethical to continue when you have such good results. Hope to see FDA approval Q4.
Just broke $4!
https://dawsonjames.com/wp-content/uploads/2021/06/CTXR.6.9.21.pdf Valuation. Our valuation is based on our therapeutic models and associated...
CTXR no doubt, over 100m in cash, data read out in 9 days